Plenary Session: Beyond Clinical Proof of Concept

What Types of Partnerships & Practices Will be Required for Commercial Success?
Given the unique development challenges for gene and cell therapy where a number of technology and process breakthroughs are occurring outside of traditional corporate structures — it is clear that strategic partnerships will play a significant role in moving beyond early clinical signals of efficacy towards versatile and robust models that can support treatment on a larger scale. This panel of pharma and biotech leaders will discuss the large volume of deals in the sector, what is driving them and how these new types of collaborations with non-traditional partners will lead to successful commercial models.

Chair:

Amy Butler, Ph.D., VP & General Manager, Cell Biology, Thermo Fisher Scientific

Speakers:

Usman Azam, M.D., Global Head, Cell & Gene Therapies Unit, Novartis
Frank Borriello, M.D., Ph.D., VP, Head of Search & Evaluation, Baxalta
Olivier Danos, Ph.D., SVP, Gene Therapy, Biogen
Perry Karsen, CEO, Celgene Cellular Therapeutics
B.G. Rhee, Ph.D., President, Green Cross Holdings